Meningitis ACWY

Meningococcal meningitis is caused by Gram-negative bacteria known as Neisseria meningitis. The disease is a systemic infection classified into 13 sub-groups, of which B, C, W135 and Y are most common in the UK. The transmission of the disease is passed on by inhaling air droplets through sneezing, coming into contact with respiratory secretions and coughing.

The bacteria are located in healthy individuals in the nasal area and usually reside harmlessly there. Globally, the highest occurrence of the disease is across the meningitis belt of sub-Saharan Africa & Saudi Arabia usually in the dry season (Dec-June). Other countries vary depending upon seasonal changes. Vaccination against Meningitis strains ACWY is mandatory for all individuals attending Hajj or Umrah. Peak Pharmacy can provide vaccination against this disease and provide the necessary certification required for your Kingdom of Saudi Arabia visa application.

Classical symptoms include:
Meningitis symptoms present with a sudden onset of fever, throbbing headache, nausea and vomiting, neck stiffness and photophobia. These symptoms last a couple of minutes to hours. If present, seek medical advice immediately. The period of incubation is approximately 2-7 days. The appearance of the rash may be not visible but as the infection develops, the rash becomes more purplish in colour and may not blanch. A simple test known as the ‘glass-test’ can confirm if the rash is persistent when gentle pressure is applied.

Vaccination dosage schedule:

Menveo: This vaccination should be administered as a single dose (0.5 ml) in children from 2 years of age. To ensure optimal antibody levels against all vaccine serogroups, the primary vaccination schedule with Menveo should be completed one month prior to the risk of exposure. The safety and efficacy of Menveo in children under 2 years of age have not yet been established.

Nimenrix: A single 0.5 ml dose of the reconstituted vaccine is used for immunisation. A booster vaccination may be given to subjects who have previously been vaccinated with a plain polysaccharide meningococcal vaccine. The safety and efficacy of Nimenrix in children under 12 months of age has not yet been established.